Atypical hemolytic uremic syndrome

Review of clinical presentation, diagnosis and management

Meera Sridharan, Ronald S. Go, Maria A.V. Willrich

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Thrombotic microangiopathies (TMA) are a class of disorders characterized by microangiopathic hemolytic anemia, non-immune thrombocytopenia, and organ dysfunction. One type of TMA is atypical hemolytic uremic syndrome (aHUS) a disorder caused by hyper-activation of the alternative complement pathway due to over activation of C3 convertases and loss of complement regulatory mechanisms. The pathophysiological mechanism of aHUS involves increased continuous spontaneous hydrolysis of C3 to C3b which leads to tissue deposition of C3b, the membrane attack complex formation and subsequent tissue injury. The underlying susceptibility factors to aHUS include acquired autoantibodies or germline mutations in complement proteins or their regulators. Currently there are no clear diagnostic criteria for aHUS. Diagnosis involves ruling out other causes of TMA and incorporating complement serologic and genetic data. TPE has been used to treat aHUS; however, clinical improvement in these patents is far less than in patients with thrombotic thrombocytopenic purpura. Furthermore, there is a higher rate of progression to end stage renal disease with almost half of patients progressing despite TPE. For those, another option for treatment is eculizumab, a monoclonal antibody that blocks complement C5. Eculizumab has proven effective in aHUS and dramatically changed the prognosis of this syndrome. In this review the clinical presentation, diagnosis and management of aHUS are highlighted with three clinical cases.

Original languageEnglish (US)
JournalJournal of Immunological Methods
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Thrombotic Microangiopathies
Complement C3-C5 Convertases
Complement C5
Alternative Complement Pathway
Complement Membrane Attack Complex
Thrombotic Thrombocytopenic Purpura
Patents
Germ-Line Mutation
Hemolytic Anemia
Atypical Hemolytic Uremic Syndrome
Thrombocytopenia
Autoantibodies
Chronic Kidney Failure
Complement System Proteins
Hydrolysis
Monoclonal Antibodies
Wounds and Injuries
eculizumab
Therapeutics

Keywords

  • Atypical hemolytic uremic syndrome
  • Complement
  • Eculizumab
  • Terminal complement inhibitor
  • Thrombotic microangiopathy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Atypical hemolytic uremic syndrome : Review of clinical presentation, diagnosis and management. / Sridharan, Meera; Go, Ronald S.; Willrich, Maria A.V.

In: Journal of Immunological Methods, 01.01.2018.

Research output: Contribution to journalArticle

@article{8b55c9ba312249a1943bd8c332c21d24,
title = "Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management",
abstract = "Thrombotic microangiopathies (TMA) are a class of disorders characterized by microangiopathic hemolytic anemia, non-immune thrombocytopenia, and organ dysfunction. One type of TMA is atypical hemolytic uremic syndrome (aHUS) a disorder caused by hyper-activation of the alternative complement pathway due to over activation of C3 convertases and loss of complement regulatory mechanisms. The pathophysiological mechanism of aHUS involves increased continuous spontaneous hydrolysis of C3 to C3b which leads to tissue deposition of C3b, the membrane attack complex formation and subsequent tissue injury. The underlying susceptibility factors to aHUS include acquired autoantibodies or germline mutations in complement proteins or their regulators. Currently there are no clear diagnostic criteria for aHUS. Diagnosis involves ruling out other causes of TMA and incorporating complement serologic and genetic data. TPE has been used to treat aHUS; however, clinical improvement in these patents is far less than in patients with thrombotic thrombocytopenic purpura. Furthermore, there is a higher rate of progression to end stage renal disease with almost half of patients progressing despite TPE. For those, another option for treatment is eculizumab, a monoclonal antibody that blocks complement C5. Eculizumab has proven effective in aHUS and dramatically changed the prognosis of this syndrome. In this review the clinical presentation, diagnosis and management of aHUS are highlighted with three clinical cases.",
keywords = "Atypical hemolytic uremic syndrome, Complement, Eculizumab, Terminal complement inhibitor, Thrombotic microangiopathy",
author = "Meera Sridharan and Go, {Ronald S.} and Willrich, {Maria A.V.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jim.2018.07.006",
language = "English (US)",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",

}

TY - JOUR

T1 - Atypical hemolytic uremic syndrome

T2 - Review of clinical presentation, diagnosis and management

AU - Sridharan, Meera

AU - Go, Ronald S.

AU - Willrich, Maria A.V.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Thrombotic microangiopathies (TMA) are a class of disorders characterized by microangiopathic hemolytic anemia, non-immune thrombocytopenia, and organ dysfunction. One type of TMA is atypical hemolytic uremic syndrome (aHUS) a disorder caused by hyper-activation of the alternative complement pathway due to over activation of C3 convertases and loss of complement regulatory mechanisms. The pathophysiological mechanism of aHUS involves increased continuous spontaneous hydrolysis of C3 to C3b which leads to tissue deposition of C3b, the membrane attack complex formation and subsequent tissue injury. The underlying susceptibility factors to aHUS include acquired autoantibodies or germline mutations in complement proteins or their regulators. Currently there are no clear diagnostic criteria for aHUS. Diagnosis involves ruling out other causes of TMA and incorporating complement serologic and genetic data. TPE has been used to treat aHUS; however, clinical improvement in these patents is far less than in patients with thrombotic thrombocytopenic purpura. Furthermore, there is a higher rate of progression to end stage renal disease with almost half of patients progressing despite TPE. For those, another option for treatment is eculizumab, a monoclonal antibody that blocks complement C5. Eculizumab has proven effective in aHUS and dramatically changed the prognosis of this syndrome. In this review the clinical presentation, diagnosis and management of aHUS are highlighted with three clinical cases.

AB - Thrombotic microangiopathies (TMA) are a class of disorders characterized by microangiopathic hemolytic anemia, non-immune thrombocytopenia, and organ dysfunction. One type of TMA is atypical hemolytic uremic syndrome (aHUS) a disorder caused by hyper-activation of the alternative complement pathway due to over activation of C3 convertases and loss of complement regulatory mechanisms. The pathophysiological mechanism of aHUS involves increased continuous spontaneous hydrolysis of C3 to C3b which leads to tissue deposition of C3b, the membrane attack complex formation and subsequent tissue injury. The underlying susceptibility factors to aHUS include acquired autoantibodies or germline mutations in complement proteins or their regulators. Currently there are no clear diagnostic criteria for aHUS. Diagnosis involves ruling out other causes of TMA and incorporating complement serologic and genetic data. TPE has been used to treat aHUS; however, clinical improvement in these patents is far less than in patients with thrombotic thrombocytopenic purpura. Furthermore, there is a higher rate of progression to end stage renal disease with almost half of patients progressing despite TPE. For those, another option for treatment is eculizumab, a monoclonal antibody that blocks complement C5. Eculizumab has proven effective in aHUS and dramatically changed the prognosis of this syndrome. In this review the clinical presentation, diagnosis and management of aHUS are highlighted with three clinical cases.

KW - Atypical hemolytic uremic syndrome

KW - Complement

KW - Eculizumab

KW - Terminal complement inhibitor

KW - Thrombotic microangiopathy

UR - http://www.scopus.com/inward/record.url?scp=85050926567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050926567&partnerID=8YFLogxK

U2 - 10.1016/j.jim.2018.07.006

DO - 10.1016/j.jim.2018.07.006

M3 - Article

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

ER -